BC Extra | Jan 28, 2020
Clinical News

Acceleron readout supports sotatercept as disease-modifying option for PAH

Acceleron is readying to send its pulmonary arterial hypertension candidate to Phase III after announcing late Monday that the therapy combined with standard of care met primary and secondary endpoints in a proof-of-concept Phase II...
BC Innovations | May 23, 2019
Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with...
BC Extra | Apr 8, 2019
Clinical News

United Therapeutics' esuberaprost fails Phase III in PAH

United Therapeutics discontinued development of esuberaprost after the compound failed to meet the primary endpoint in the Phase III BEAT trial to treat pulmonary arterial hypertension. Esuberaprost is a single isomer formulation of beraprost, a...
BC Extra | Jul 26, 2017
Company News

Lilly stretches Olumiant timeline, updates cancer strategy

Eli Lilly and Co. (NYSE:LLY) reported 2Q17 earnings and said it would delay its plans to resubmit an NDA for Olumiant baricitinib beyond 2017. The company also said it would narrow its oncology focus to...
BC Week In Review | Apr 21, 2017
Company News

Respira, United Therapeutics deal

Respira granted United Therapeutics exclusive, North American rights to RT234 to treat pulmonary hypertension. United Therapeutics will provide funding to Respira to develop RT234 through approval and United Therapeutics will be responsible for commercialization. The...
BC Innovations | Feb 28, 2017
Distillery Techniques

Assays and screens

TECHNOLOGY: Cell-free assays A synaptosome-based assay of long-term synaptic potentiation could be used to screen therapies to treat AD. The assay involved isolating synaptosomes from frozen, postmortem parietal cortex samples from AD patients and unaffected...
BC Week In Review | Feb 8, 2017
Clinical News

Tadalafil PharmFilm regulatory update

MonoSol said FDA accepted for review an NDA for Tadalafil Oral Soluble Film (OSF) to treat erectile dysfunction (ED). The PDUFA date is Sept. 18. The product is a film formulation of tadalafil, a phosphodiesterase-5...
BC Week In Review | Dec 30, 2016
Company News

Lilly joins cTAP consortium

The Collaborative Trajectory Analysis Project (cTAP) said Eli Lilly has joined the consortium. The group, which includes scientists, drug companies, patient advocacy organizations and clinical centers, is collaborating to advance treatments for Duchenne muscular dystrophy...
BC Extra | Dec 22, 2016
Company News

Lilly joins DMD consortium

The Collaborative Trajectory Analysis Project (cTAP) said Eli Lilly and Co. (NYSE:LLY) has joined the consortium. The group, which includes scientists, drug companies, patient advocacy organizations and clinical centers, is collaborating to advance treatments for...
BC Week In Review | Dec 2, 2016
Company News

Lilly, IntelGenx deal

Eli Lilly granted IntelGenx rights to U.S. Patent No. 6,943,166, which covers dosing of Lilly’s tadalafil. IntelGenx says the deal will allow it to commercialize its Tadalafil ED Versafilm in the U.S. before the expiration...
Items per page:
1 - 10 of 373